Autopsy report · NCT01659021
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Cause of deathNo reason given
Life of this trial
- Registered 4 months before it started.
- Ran for about 5 years 8 months before it stopped.
- 261 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Idelalisib; Ofatumumab
- Participants
- 261
- Sites
- 80
- Countries
- Australia, Belgium, Canada, Denmark, France, Ireland, Poland, Spain, Sweden, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.